| Improved titer and gene transfer by lentiviral vectors using novel, small β-globin locus control region elements RA Morgan, MJ Unti, B Aleshe, D Brown, KS Osborne, C Koziol, ... Molecular Therapy 28 (1), 328-340, 2020 | 44 | 2020 |
| Outcomes following treatment for ADA-deficient severe combined immunodeficiency: a report from the PIDTC GDE Cuvelier, BR Logan, SE Prockop, RH Buckley, CY Kuo, LM Griffith, ... Blood, The Journal of the American Society of Hematology 140 (7), 685-705, 2022 | 34 | 2022 |
| Previous infection combined with vaccination produces neutralizing antibodies with potency against SARS-CoV-2 variants FJ Ibarrondo, C Hofmann, A Ali, P Ayoub, DB Kohn, OO Yang Mbio 12 (6), e02656-21, 2021 | 16 | 2021 |
| Creating new β-globin-expressing lentiviral vectors by high-resolution mapping of locus control region enhancer sequences RA Morgan, F Ma, MJ Unti, D Brown, PG Ayoub, C Tam, L Lathrop, ... Molecular therapy Methods & clinical development 17, 999-1013, 2020 | 15 | 2020 |
| Gene therapy for β-hemoglobinopathies: From discovery to clinical trials EER Segura, PG Ayoub, KL Hart, DB Kohn Viruses 15 (3), 713, 2023 | 12 | 2023 |
| Global and local manipulation of DNA repair mechanisms to alter site-specific gene editing outcomes in hematopoietic stem cells EK Benitez, A Lomova Kaufman, L Cervantes, DN Clark, PG Ayoub, ... Frontiers in Genome Editing 2, 601541, 2020 | 11 | 2020 |
| Improved SARS-CoV-2 spike glycoproteins for pseudotyping lentiviral vectors PG Ayoub, A Purkayastha, J Quintos, C Tam, L Lathrop, K Tam, M Ruiz, ... Frontiers in Virology 1, 793320, 2021 | 4 | 2021 |
| Lentiviral vectors for precise expression to treat X-linked lymphoproliferative disease PG Ayoub, J Gensheimer, L Lathrop, C Juett, J Quintos, K Tam, J Reid, ... Molecular Therapy Methods & Clinical Development 32 (4), 2024 | 1 | 2024 |
| Improved SARS-CoV-2 Spike Glycoproteins for Pseudotyping Lentiviral Vectors PG Ayoub, J Quintos, RP Hollis, DB Kohn Available at SSRN 3758210, 2020 | 1 | 2020 |
| Lipid Nanoparticles for the Delivery of CRISPR/Cas9 Machinery to Enable Site-Specific Integration of CFTR and Mutation-Agnostic Disease Rescue RA Foley, PG Ayoub, V Sinha, C Juett, A Sanoyca, EC Duggan, ... bioRxiv, 2025.01. 22.633938, 2025 | | 2025 |
| 290 Cargo-agnostic lipid nanoparticles for universal correction of cystic fibrosis-causing mutations in bronchial epithelial cells R Foley, P Ayoub, A Sanoyca, C Juett, V Sinha, C Cherry, E Duggan, ... Journal of Cystic Fibrosis 23, S154-S155, 2024 | | 2024 |
| 263 A lipid nanoparticle arsenal to correct cystic fibrosis in airway stem cells R Foley, P Ayoub, E Duggan, J Khorsandi, D Banuet, A Purkayastha, ... Journal of Cystic Fibrosis 22, S133-S134, 2023 | | 2023 |
| β-Thalassemia: all about that base, no cutting PG Ayoub, DB Kohn Blood, The Journal of the American Society of Hematology 141 (10), 1098-1099, 2023 | | 2023 |
| Advancing Gene Therapy Technologies for the Treatment of Genetic Disorders PG Ayoub University of California, Los Angeles, 2023 | | 2023 |
| The Effects of Manipulating DNA Repair Factors on CRISPR/Cas9-Mediated Gene Editing Outcomes in Human Hematopoietic Stem and Progenitor Cells A Lomova, EK Benitez, DN Clark, P Ayoub, Z Romero, RP Hollis, ... MOLECULAR THERAPY 27 (4), 352-352, 2019 | | 2019 |
